828 related articles for article (PubMed ID: 30618179)
41. Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial.
Moreno V; Roda D; Pikiel J; Trigo J; Bosch-Barrera J; Drew Y; Kristeleit R; Hiret S; Bajor DL; Cruz P; Beck JT; Ghosh S; Dabrowski C; Antony G; Duan T; Veneris J; Zografos E; Subramanian J
Clin Lung Cancer; 2022 Nov; 23(7):e415-e427. PubMed ID: 35729005
[TBL] [Abstract][Full Text] [Related]
42. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study.
de Castro G; Kudaba I; Wu YL; Lopes G; Kowalski DM; Turna HZ; Caglevic C; Zhang L; Karaszewska B; Laktionov KK; Srimuninnimit V; Bondarenko I; Kubota K; Mukherjee R; Lin J; Souza F; Mok TSK; Cho BC
J Clin Oncol; 2023 Apr; 41(11):1986-1991. PubMed ID: 36306479
[No Abstract] [Full Text] [Related]
43. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.
Aguilar EJ; Ricciuti B; Gainor JF; Kehl KL; Kravets S; Dahlberg S; Nishino M; Sholl LM; Adeni A; Subegdjo S; Khosrowjerdi S; Peterson RM; Digumarthy S; Liu C; Sauter J; Rizvi H; Arbour KC; Carter BW; Heymach JV; Altan M; Hellmann MD; Awad MM
Ann Oncol; 2019 Oct; 30(10):1653-1659. PubMed ID: 31435660
[TBL] [Abstract][Full Text] [Related]
44. Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study.
Herbst RS; Garon EB; Kim DW; Cho BC; Perez-Gracia JL; Han JY; Arvis CD; Majem M; Forster MD; Monnet I; Novello S; Szalai Z; Gubens MA; Su WC; Ceresoli GL; Samkari A; Jensen EH; Lubiniecki GM; Baas P
J Clin Oncol; 2020 May; 38(14):1580-1590. PubMed ID: 32078391
[TBL] [Abstract][Full Text] [Related]
45. Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
Cortellini A; Cannita K; Tiseo M; Cortinovis DL; Aerts JGJV; Baldessari C; Giusti R; Ferrara MG; D'Argento E; Grossi F; Guida A; Berardi R; Morabito A; Genova C; Antonuzzo L; Mazzoni F; De Toma A; Signorelli D; Gelibter A; Targato G; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Mansueto G; Zoratto F; Filetti M; Bracarda S; Citarella F; Russano M; Cantini L; Nigro O; Buti S; Minuti G; Landi L; Ricciardi S; Migliorino MR; Natalizio S; Simona C; De Filippis M; Metro G; Adamo V; Russo A; Spinelli GP; Di Maio M; Banna GL; Friedlaender A; Addeo A; Pinato DJ; Ficorella C; Porzio G
Eur J Cancer; 2021 May; 148():24-35. PubMed ID: 33721704
[TBL] [Abstract][Full Text] [Related]
46. Programmed Death-Ligand 1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Nonsquamous Versus Squamous NSCLC.
Doroshow DB; Wei W; Gupta S; Zugazagoitia J; Robbins C; Adamson B; Rimm DL
J Thorac Oncol; 2021 Dec; 16(12):2139-2143. PubMed ID: 34455068
[TBL] [Abstract][Full Text] [Related]
47. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.
Muro K; Chung HC; Shankaran V; Geva R; Catenacci D; Gupta S; Eder JP; Golan T; Le DT; Burtness B; McRee AJ; Lin CC; Pathiraja K; Lunceford J; Emancipator K; Juco J; Koshiji M; Bang YJ
Lancet Oncol; 2016 Jun; 17(6):717-726. PubMed ID: 27157491
[TBL] [Abstract][Full Text] [Related]
48. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.
Lisberg A; Cummings A; Goldman JW; Bornazyan K; Reese N; Wang T; Coluzzi P; Ledezma B; Mendenhall M; Hunt J; Wolf B; Jones B; Madrigal J; Horton J; Spiegel M; Carroll J; Gukasyan J; Williams T; Sauer L; Wells C; Hardy A; Linares P; Lim C; Ma L; Adame C; Garon EB
J Thorac Oncol; 2018 Aug; 13(8):1138-1145. PubMed ID: 29874546
[TBL] [Abstract][Full Text] [Related]
49. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Sezer A; Kilickap S; Gümüş M; Bondarenko I; Özgüroğlu M; Gogishvili M; Turk HM; Cicin I; Bentsion D; Gladkov O; Clingan P; Sriuranpong V; Rizvi N; Gao B; Li S; Lee S; McGuire K; Chen CI; Makharadze T; Paydas S; Nechaeva M; Seebach F; Weinreich DM; Yancopoulos GD; Gullo G; Lowy I; Rietschel P
Lancet; 2021 Feb; 397(10274):592-604. PubMed ID: 33581821
[TBL] [Abstract][Full Text] [Related]
50. Clinical outcomes of pembrolizumab therapy in advanced-NSCLC patients with poor performance status (≥3) and high PD-L1 expression (TPS ≥50%): A case series.
Inaba-Higashiyama R; Yoshida T; Jo H; Shirasawa M; Motoi N; Ohe Y
Thorac Cancer; 2020 Dec; 11(12):3618-3621. PubMed ID: 33085191
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression.
Wakuda K; Yabe M; Kodama H; Nishioka N; Miyawaki T; Miyawaki E; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Ono A; Kenmotsu H; Naito T; Murakami H; Harada H; Endo M; Gon Y; Takahashi T
Lung Cancer; 2021 Jan; 151():60-68. PubMed ID: 33246646
[TBL] [Abstract][Full Text] [Related]
52. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.
Zhou Y; Lin Z; Zhang X; Chen C; Zhao H; Hong S; Zhang L
J Immunother Cancer; 2019 May; 7(1):120. PubMed ID: 31053172
[TBL] [Abstract][Full Text] [Related]
53. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.
Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Leal TA; Riess JW; Jensen E; Zhao B; Pietanza MC; Brahmer JR
J Clin Oncol; 2021 Jul; 39(21):2339-2349. PubMed ID: 33872070
[TBL] [Abstract][Full Text] [Related]
54. Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis.
Torasawa M; Yoshida T; Yagishita S; Shimoda Y; Shirasawa M; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Takahashi K; Ohe Y
Lung Cancer; 2022 May; 167():49-57. PubMed ID: 35397298
[TBL] [Abstract][Full Text] [Related]
55. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
Alley EW; Lopez J; Santoro A; Morosky A; Saraf S; Piperdi B; van Brummelen E
Lancet Oncol; 2017 May; 18(5):623-630. PubMed ID: 28291584
[TBL] [Abstract][Full Text] [Related]
56. Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial.
Middleton G; Brock K; Savage J; Mant R; Summers Y; Connibear J; Shah R; Ottensmeier C; Shaw P; Lee SM; Popat S; Barrie C; Barone G; Billingham L
Lancet Respir Med; 2020 Sep; 8(9):895-904. PubMed ID: 32199466
[TBL] [Abstract][Full Text] [Related]
57. First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
Satouchi M; Nosaki K; Takahashi T; Nakagawa K; Aoe K; Kurata T; Sekine A; Horiike A; Fukuhara T; Sugawara S; Umemura S; Saka H; Okamoto I; Yamamoto N; Sakai H; Kishi K; Katakami N; Horinouchi H; Hida T; Okamoto H; Atagi S; Ohira T; Rong Han S; Noguchi K; Ebiana V; Hotta K
Cancer Sci; 2021 Dec; 112(12):5000-5010. PubMed ID: 34543477
[TBL] [Abstract][Full Text] [Related]
58. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.
Ott PA; Bang YJ; Berton-Rigaud D; Elez E; Pishvaian MJ; Rugo HS; Puzanov I; Mehnert JM; Aung KL; Lopez J; Carrigan M; Saraf S; Chen M; Soria JC
J Clin Oncol; 2017 Aug; 35(22):2535-2541. PubMed ID: 28489510
[TBL] [Abstract][Full Text] [Related]
59. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Gadgeel S; Rodríguez-Abreu D; Speranza G; Esteban E; Felip E; Dómine M; Hui R; Hochmair MJ; Clingan P; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Garon EB; Novello S; Rubio-Viqueira B; Boyer M; Kurata T; Gray JE; Yang J; Bas T; Pietanza MC; Garassino MC
J Clin Oncol; 2020 May; 38(14):1505-1517. PubMed ID: 32150489
[TBL] [Abstract][Full Text] [Related]
60. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
Imai H; Kishikawa T; Minemura H; Yamada Y; Ibe T; Yamaguchi O; Mouri A; Hamamoto Y; Kanazawa K; Kasai T; Kaira K; Kaburagi T; Minato K; Kobayashi K; Kagamu H
Cancer Med; 2021 Oct; 10(20):6971-6984. PubMed ID: 34414673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
